title: [MDR reversing drugs for clinical development].
abstract: Since we discovered verapamil as an MDR-reversing agent in 1981, many MDR-reversing compounds have been reported. This type of drug must be very effective but minimal side effects. We recently found that MS-209 and PSC-833 to be reversing agents that interact directly with P-glycoprotein and show good MDR-reversing effect, both in vitro and in vivo. MS-209 and PSC-833 are thus interesting compounds for clinical use in future.
authors.affiliation: Institute of Molecular and Cellular Biosciences, University of Tokyo.
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003524:Cyclosporins / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D004357:Drug Synergism; D006801:Humans; D007941:Leukemia P388 / Q000473:pathology; D051379:Mice; D011804:Quinolines / Q000494:pharmacology*; D014700:Verapamil / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D003524:Cyclosporins; D011804:Quinolines; C087719:dofequidar; D004317:Doxorubicin; D014700:Verapamil; C070272:valspodar